Ikehata A, Hiwatashi N, Kinouchi Y, Yamazaki H, Kumagai Y, Ito K, Kayaba Y, Toyota T
Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Am J Clin Nutr. 1992 Nov;56(5):938-42. doi: 10.1093/ajcn/56.5.938.
Ten patients with active Crohn's disease who have been managed with parenteral-nutrition therapy were administered a lipid emulsion either with [containing 0.6 g eicosapentaenoic acid (EPA)] or without fish oil for 2 wk. We isolated polymorphonuclear leukocytes (PMNLs) from the patients before and after this treatment and measured the amounts of leukotriene B4 (LTB4) and leukotriene B5 (LTB5) generated by activated PMNLs by reversed-phase HPLC. The LTB5 generation in active Crohn's disease before this treatment was significantly lower than in healthy control subjects. The amount of LTB5 and the LTB5-LTB4 ratio increased significantly after fish-oil supplementation. The difference with LTB4 was not statistically significant. We have shown that daily intravenous administration of 0.6 g EPA influenced the generation of leukotrienes in active Crohn's disease even after short-term treatment. Further investigations are necessary to clarify the correlation between EPA and clinical improvement in Crohn's disease.
对10例接受肠外营养治疗的活动期克罗恩病患者给予含或不含鱼油的脂质乳剂(含0.6 g二十碳五烯酸[EPA]),为期2周。我们在治疗前后从患者体内分离出多形核白细胞(PMNLs),并通过反相高效液相色谱法测定活化的PMNLs产生的白三烯B4(LTB4)和白三烯B5(LTB5)的量。治疗前活动期克罗恩病患者的LTB5生成量显著低于健康对照者。补充鱼油后,LTB5的量和LTB5-LTB4比值显著增加。与LTB4的差异无统计学意义。我们已经表明,即使经过短期治疗,每日静脉注射0.6 g EPA也会影响活动期克罗恩病患者白三烯的生成。有必要进一步研究以阐明EPA与克罗恩病临床改善之间的相关性。